This trial is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals. The study will evaluate the safety, tolerability, and immunogenicity of 3 different SARS-CoV-2 RNA vaccine candidates against COVID-19 and the efficacy of 1 candidate.
The FDA has approved a 10 µg dose of a medication for use in treating COVID-19 in adults aged 18-55. This dose is to be given in two doses as the primary treatment for the disease. This medication has previously been approved by the FDA for use in treating a different condition.
Phase 2 & 3